Andrew Schwab Biography and Net Worth

Mr. Schwab has led investments in numerous biotech companies such as Bird Rock Bio, Camp4 Therapeutics, DVS (acquired by Fluidigm), Enliven (NASDAQ ELVN), Escient Pharmaceuticals, and Flexion Therapeutics (acquired by Pacira), among others. Before the formation of 5AM in 2002, Schwab was a Principal at Bay City Capital where he contributed to the growth of companies like Cubist, PTC Therapeutics, and Syrrx. His past roles also include Vice President of Business Development at Digital Gene Technologies and a vice president in the life science investment banking group of Montgomery Securities. In 2021, he became a board member at Pear Therapeutics. Concurrently, he has been serving as co-Chief Executive Officer and a member of the board of directors of 5:01 Acquisition Corp. (Nasdaq: FVAM) since its inception in August 2020. Schwab earned a BS with Honors in Genetics & Ethics from Davidson College and currently serves on its board of trustees as well as the Board of Trustees of the California Academy of Sciences.

What is Andrew J. Schwab's net worth?

The estimated net worth of Andrew J. Schwab is at least $7.51 thousand as of September 22nd, 2026. Mr. Schwab owns 4,528 shares of Skye Bioscience stock worth more than $7,512 as of October 7th. This net worth approximation does not reflect any other investments that Mr. Schwab may own. Learn More about Andrew J. Schwab's net worth.

How do I contact Andrew J. Schwab?

The corporate mailing address for Mr. Schwab and other Skye Bioscience executives is 11250 EL Camino Real, Suite 100, San Diego, CA, 92130. Skye Bioscience can also be reached via phone at 858-410-0266 and via email at [email protected]. Learn More on Andrew J. Schwab's contact information.

Has Andrew J. Schwab been buying or selling shares of Skye Bioscience?

Andrew J. Schwab has not been actively trading shares of Skye Bioscience within the last three months. Most recently, Andrew J. Schwab sold 119,379 shares of the business's stock in a transaction on Wednesday, September 23rd. The shares were sold at an average price of $1.61, for a transaction totalling $192,200.19. Learn More on Andrew J. Schwab's trading history.

Are insiders buying or selling shares of Skye Bioscience?

In the last twelve months, insiders at the sold shares 12 times. They sold a total of 457,900 shares worth more than $889,198.46. The most recent insider tranaction occured on September, 23rd when Director Andrew J. Schwab sold 119,379 shares worth more than $192,200.19. Insiders at Skye Bioscience own 6.2% of the company. Learn More about insider trades at Skye Bioscience.

Information on this page was last updated on 9/23/2026.